{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:54:08Z","timestamp":1790996048086,"version":"4.1.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"DOI":"10.1007\/s11912-026-01834-y","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:14:47Z","timestamp":1790932487000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interventional Management of Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis: Are There Differences Between East and West?"],"prefix":"10.1007","volume":"28","author":[{"given":"Rong","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gao-Jun","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"issue":"10127","key":"1834_CR1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","volume":"391","author":"A Forner","year":"2018","unstructured":"Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301\u201314. https:\/\/doi.org\/10.1016\/S0140-6736(18)30010-2.","journal-title":"Lancet"},{"issue":"10360","key":"1834_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","volume":"400","author":"A Vogel","year":"2022","unstructured":"Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(22)01200-4.","journal-title":"Lancet"},{"key":"1834_CR3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13045-021-01036-y","volume":"14","author":"X Su","year":"2021","unstructured":"Su X, Zhao L, Shi Y, Zhang R, Long Q, Bai S, et al. Clonal evolution in liver cancer at single-cell and single-variant resolution. J Hematol Oncol. 2021;14:2.","journal-title":"J Hematol Oncol."},{"issue":"4","key":"1834_CR4","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.jhep.2021.04.053","volume":"75","author":"HC Zhou","year":"2021","unstructured":"Zhou HC, Liu CX, Pan WD, Shang LR, Zheng JL, Huang BY, et al. Dual and opposing roles of the androgen receptor in VETC-dependent and invasion-dependent metastasis of hepatocellular carcinoma. J Hepatol. 2021;75(4):900\u201311. https:\/\/doi.org\/10.1016\/j.jhep.2021.04.053.","journal-title":"J Hepatol."},{"key":"1834_CR5","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12943-023-01882-z","volume":"22","author":"L Xu","year":"2023","unstructured":"Xu L, Wang P, Li L, Li L, Huang Y, Zhang Y, et al. circPSD3 is a promising inhibitor of uPA system to inhibit vascular invasion and metastasis in hepatocellular carcinoma. Mol Cancer. 2023;22:174.","journal-title":"Mol Cancer."},{"key":"1834_CR6","first-page":"47","volume":"4","author":"B Han","year":"2024","unstructured":"Han B, Zheng R, Zeng H, Wang S, Sun K, Chen R, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent. 2024;4:47\u201353.","journal-title":"J Natl Cancer Cent."},{"key":"1834_CR7","first-page":"203","volume":"4","author":"H Zeng","year":"2024","unstructured":"Zeng H, Zheng R, Sun K, Zhou M, Wang S, Li L, et al. Cancer survival statistics in China 2019\u20132021: a multicenter, population-based study. J Natl Cancer Cent. 2024;4:203\u201313.","journal-title":"J Natl Cancer Cent."},{"key":"1834_CR8","doi-asserted-by":"crossref","unstructured":"Shan T, Ran X, Li H, Feng G, Zhang S, Zhang X, et al. Disparities in stage at diagnosis for liver cancer in China. J Natl Cancer Cent. 2023;7\u201313.","DOI":"10.1016\/j.jncc.2022.12.002"},{"issue":"8","key":"1834_CR9","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","volume":"23","author":"RK Kelley","year":"2022","unstructured":"Kelley RK, Rimassa L, Cheng AL, Kaseb A, Qin S, Zhu AX, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(8):995\u20131008. https:\/\/doi.org\/10.1016\/S1470-2045(22)00326-6.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1834_CR10","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/S1470-2045(20)30156-X","volume":"21","author":"MS Lee","year":"2020","unstructured":"Lee MS, Ryoo BY, Hsu CH, Numata K, Stein S, Verret W, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020;21(6):808\u201320. https:\/\/doi.org\/10.1016\/S1470-2045(20)30156-X.","journal-title":"Lancet Oncol"},{"key":"1834_CR11","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1200\/JCO.20.00808","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, et al. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. J Clin Oncol. 2020;38:2960\u201370.","journal-title":"J Clin Oncol."},{"issue":"3","key":"1834_CR12","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jhep.2025.10.020","volume":"84","author":"M Reig","year":"2026","unstructured":"Reig M, Sanduzzi-Zamparelli M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, et al. BCLC strategy for prognosis prediction and treatment recommendations: the 2026 update. J Hepatol. 2026;84(3):631\u201354. https:\/\/doi.org\/10.1016\/j.jhep.2025.10.020.","journal-title":"J Hepatol"},{"key":"1834_CR13","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78:1922\u201365.","journal-title":"Hepatology."},{"key":"1834_CR14","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","volume":"18","author":"B Sangro","year":"2024","unstructured":"Sangro B, Sarobe P, Hervas-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2024;18:525\u201343.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"1834_CR15","doi-asserted-by":"crossref","unstructured":"Dual Immunotherapy Makes Strides against HCC. Cancer Discov. 2022;12;OF1.","DOI":"10.1158\/2159-8290.CD-NB2022-0008"},{"issue":"10408","key":"1834_CR16","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023;402(10408):1133\u201346. https:\/\/doi.org\/10.1016\/S0140-6736(23)00961-3.","journal-title":"Lancet"},{"key":"1834_CR17","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13045-025-01739-6","volume":"18","author":"S Dai","year":"2025","unstructured":"Dai S, Chen Y, Cai W, Dong S, Zhao J, Chen L, et al. Combination immunotherapy in hepatocellular carcinoma: synergies among immune checkpoints, TKIs, and chemotherapy. J Hematol Oncol. 2025;18:85.","journal-title":"J Hematol Oncol."},{"key":"1834_CR18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","volume":"19","author":"JM Llovet","year":"2022","unstructured":"Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19:151\u201372.","journal-title":"Nat Rev Clin Oncol."},{"issue":"2","key":"1834_CR19","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jhep.2023.03.003","volume":"79","author":"L Rimassa","year":"2023","unstructured":"Rimassa L, Finn RS, Sangro B. Combination immunotherapy for hepatocellular carcinoma. J Hepatol. 2023;79(2):506\u201315. https:\/\/doi.org\/10.1016\/j.jhep.2023.03.003.","journal-title":"J Hepatol"},{"key":"1834_CR20","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","volume":"18","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18:293\u2013313.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"1834_CR21","unstructured":"Clinical Guidelines Committee of Chinese College of I. [Chinese clinical practice guidelines for transarterial chemoembolization of hepatocellular carcinoma (2023 edition)]. Zhonghua Yi Xue Za Zhi. 2023;103(34):2674\u201394.\u00a0https:\/\/doi.org\/10.3760\/cma.j.cn112137-20230630-01114."},{"key":"1834_CR22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3348\/kjr.2022.0510","volume":"24","author":"IJ Lee","year":"2023","unstructured":"Lee IJ, Chun HJ, Chung JW. 2022 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for Transarterial Therapy of Hepatocellular Carcinoma: What\u2019s New? Korean J Radiol. 2023;24:6\u20139.","journal-title":"Korean J Radiol."},{"key":"1834_CR23","unstructured":"Department of Medical Administration NHCotPsRoC. Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2026 Edition). Medical Journal of Peking Union Medical College Hospital. 2026;17(3): 735\u2013770.\u00a0https:\/\/doi.org\/10.12290\/xhyxzz.2026-0487."},{"key":"1834_CR24","doi-asserted-by":"publisher","first-page":"593","DOI":"10.3350\/cmh.2022.0391","volume":"29","author":"H Iwamoto","year":"2023","unstructured":"Iwamoto H, Shimose S, Shirono T, Niizeki T, Kawaguchi T. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity. Clin Mol Hepatol. 2023;29:593\u2013604.","journal-title":"Clin Mol Hepatol."},{"key":"1834_CR25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01737","author":"M Gelli","year":"2026","unstructured":"Gelli M, Ewald J, Tanguy ML, Passot G, Quenet F, Touchefeu Y, et al. Postoperative hepatic arterial infusion with oxaliplatin after surgery of four or more colorectal liver metastases: a randomized phase II trial. J Clin Oncol. 2026. https:\/\/doi.org\/10.1200\/JCO-25-01737.","journal-title":"J Clin Oncol"},{"key":"1834_CR26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.canlet.2021.10.036","volume":"525","author":"S Zhao","year":"2022","unstructured":"Zhao S, Huang L, Basu P, Domingo EJ, Supakarapongkul W, Ling WY, et al. Cervical cancer burden, status of implementation and challenges of cervical cancer screening in Association of Southeast Asian Nations (ASEAN) countries. Cancer Lett. 2022;525:22\u201332. https:\/\/doi.org\/10.1016\/j.canlet.2021.10.036.","journal-title":"Cancer Lett"},{"issue":"3","key":"1834_CR27","doi-asserted-by":"publisher","first-page":"e416","DOI":"10.1016\/S2214-109X(21)00595-7","volume":"10","author":"YC Kong","year":"2022","unstructured":"Kong YC, Kimman M, Subramaniam S, Yip CH, Jan S, Aung S, et al. Out-of-pocket payments for complementary medicine following cancer and the effect on financial outcomes in middle-income countries in southeast Asia: a prospective cohort study. Lancet Glob Health. 2022;10(3):e416\u201328. https:\/\/doi.org\/10.1016\/S2214-109X(21)00595-7.","journal-title":"Lancet Glob Health."},{"key":"1834_CR28","doi-asserted-by":"publisher","first-page":"S228","DOI":"10.3350\/cmh.2024.0824","volume":"31","author":"SY Hwang","year":"2025","unstructured":"Hwang SY, Danpanichkul P, Agopian V, Mehta N, Parikh ND, Abou-Alfa GK, et al. Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment. Clin Mol Hepatol. 2025;31:S228\u201354.","journal-title":"Clin Mol Hepatol."},{"issue":"1","key":"1834_CR29","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1200\/JCO.22.00392","volume":"41","author":"Z Peng","year":"2023","unstructured":"Peng Z, Fan W, Zhu B, Wang G, Sun J, Xiao C, et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH). J Clin Oncol. 2023;41(1):117\u201327. https:\/\/doi.org\/10.1200\/JCO.22.00392.","journal-title":"J Clin Oncol"},{"key":"1834_CR30","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1097\/JS9.0000000000000295","volume":"109","author":"J Lu","year":"2023","unstructured":"Lu J, Guo JH, Ji JS, Li YL, Lv WF, Zhu HD, et al. Irradiation stent with 125 I plus TACE versus sorafenib plus TACE for hepatocellular carcinoma with major portal vein tumor thrombosis: a multicenter randomized trial. Int J Surg. 2023;109:1188\u201398.","journal-title":"Int J Surg."},{"key":"1834_CR31","doi-asserted-by":"publisher","first-page":"7860","DOI":"10.1097\/JS9.0000000000001819","volume":"110","author":"M Cai","year":"2024","unstructured":"Cai M, Liang L, Zhang J, Chen N, Huang W, Guo Y, et al. Lenvatinib plus drug-eluting bead transarterial chemoembolization with\/without hepatic arterial infusion chemotherapy for hepatocellular carcinoma larger than 7 cm with major portal vein tumor thrombosis: a multicenter retrospective cohort study. Int J Surg. 2024;110:7860\u201370.","journal-title":"Int J Surg."},{"key":"1834_CR32","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1097\/JS9.0000000000000256","volume":"109","author":"Y Yuan","year":"2023","unstructured":"Yuan Y, He W, Yang Z, Qiu J, Huang Z, Shi Y, et al. TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study. Int J Surg. 2023;109:1222\u201330.","journal-title":"Int J Surg."},{"issue":"6","key":"1834_CR33","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.jvir.2017.02.014","volume":"28","author":"J Lu","year":"2017","unstructured":"Lu J, Guo JH, Zhu HD, Zhu GY, Chen L, Teng GJ. Safety and efficacy of irradiation stent placement for malignant portal vein thrombus combined with transarterial chemoembolization for hepatocellular carcinoma: a single-center experience. J Vasc Interv Radiol. 2017;28(6):786-94 e3. https:\/\/doi.org\/10.1016\/j.jvir.2017.02.014.","journal-title":"J Vasc Interv Radiol"},{"key":"1834_CR34","doi-asserted-by":"crossref","unstructured":"Cheng S, Chen M, Cai J, Sun J, Guo R, Bi X, et al. Chinese Expert Consensus on Multidisciplinary Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus (2018 Edition). Liver Cancer. 2020;9:28\u201340.","DOI":"10.1159\/000503685"},{"key":"1834_CR35","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jvir.2010.11.029","volume":"22","author":"J Luo","year":"2011","unstructured":"Luo J, Yan Z, Liu Q, Qu X, Wang J. Endovascular placement of iodine-125 seed strand and stent combined with chemoembolization for treatment of hepatocellular carcinoma with tumor thrombus in main portal vein. J Vasc Interv Radiol. 2011;22:479\u201389.","journal-title":"J Vasc Interv Radiol."},{"key":"1834_CR36","doi-asserted-by":"publisher","first-page":"12108","DOI":"10.18632\/oncotarget.14520","volume":"8","author":"TZ Yu","year":"2017","unstructured":"Yu TZ, Zhang W, Liu QX, Li WH, Ma JQ, Zhang ZH, et al. Endovascular brachytherapy combined with portal vein stenting and transarterial chemoembolization improves overall survival of hepatocellular carcinoma patients with main portal vein tumor thrombus. Oncotarget. 2017;8:12108\u201319.","journal-title":"Oncotarget."},{"key":"1834_CR37","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s12072-015-9663-8","volume":"10","author":"JJ Luo","year":"2016","unstructured":"Luo JJ, Zhang ZH, Liu QX, Zhang W, Wang JH, Yan ZP. Endovascular brachytherapy combined with stent placement and TACE for treatment of HCC with main portal vein tumor thrombus. Hepatol Int. 2016;10:185\u201395.","journal-title":"Hepatol Int"},{"key":"1834_CR38","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","volume":"33","author":"PJ Johnson","year":"2015","unstructured":"Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33:550\u20138.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1834_CR39","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jhep.2016.09.008","volume":"66","author":"DJ Pinato","year":"2017","unstructured":"Pinato DJ, Sharma R, Allara E, Yen C, Arizumi T, Kubota K, et al. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. J Hepatol. 2017;66(2):338\u201346. https:\/\/doi.org\/10.1016\/j.jhep.2016.09.008.","journal-title":"J Hepatol"},{"issue":"2","key":"1834_CR40","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jhep.2019.09.023","volume":"72","author":"DH Palmer","year":"2020","unstructured":"Palmer DH, Malagari K, Kulik LM. Role of locoregional therapies in the wake of systemic therapy. J Hepatol. 2020;72(2):277\u201387. https:\/\/doi.org\/10.1016\/j.jhep.2019.09.023.","journal-title":"J Hepatol."},{"key":"1834_CR41","first-page":"498","volume":"75","author":"D Moris","year":"2025","unstructured":"Moris D, Martinino A, Schiltz S, Allen PJ, Barbas A, Sudan D, et al. Advances in the treatment of hepatocellular carcinoma: an overview of the current and evolving therapeutic landscape for clinicians. CA Cancer J Clin. 2025;75:498\u2013527.","journal-title":"CA Cancer J Clin"},{"key":"1834_CR42","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41392-025-02400-x","volume":"10","author":"K Jin","year":"2025","unstructured":"Jin K, Zeng S, Li B, Zhang G, Wu J, Hu X, et al. Bicarbonate-integrated transarterial chemoembolization (TACE) in real-world hepatocellular carcinoma. Signal Transduct Target Ther. 2025;10:281.","journal-title":"Signal Transduct Target Ther."},{"key":"1834_CR43","doi-asserted-by":"crossref","unstructured":"Zhou J, Sun H, Wang Z, Cong W, Zeng M, Zhou W, et al. China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition). Liver Cancer. 2025;14:779\u2013835.","DOI":"10.1159\/000546574"},{"key":"1834_CR44","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the L. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025;82(2):315\u201374.\u00a0https:\/\/doi.org\/10.1016\/j.jhep.2024.08.028.","DOI":"10.1016\/j.jhep.2024.08.028"},{"key":"1834_CR45","doi-asserted-by":"crossref","unstructured":"Shao G, Zou Y, Lucatelli P, Tsilimigras DI, Shimise S, Kawaguchi T. Chinese expert consensus on technical recommendations for the standard operation of drug-eluting beads for transvascular embolization. Ann Transl Med. 2021;9:714.","DOI":"10.21037\/atm-21-1678"},{"key":"1834_CR46","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1001\/jamasurg.2024.0506","volume":"159","author":"Z Peng","year":"2024","unstructured":"Peng Z, Fan W, Liu Z, Xiao H, Wu J, Tang R, et al. Adjuvant Transarterial Chemoembolization With Sorafenib for Portal Vein Tumor Thrombus: A Randomized Clinical Trial. JAMA Surg. 2024;159:616\u201324.","journal-title":"JAMA Surg."},{"key":"1834_CR47","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41392-022-01235-0","volume":"8","author":"HD Zhu","year":"2023","unstructured":"Zhu HD, Li HL, Huang MS, Yang WZ, Yin GW, Zhong BY, et al. Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). Signal Transduct Target Ther. 2023;8:58.","journal-title":"Signal Transduct Target Ther."},{"key":"1834_CR48","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1200\/JCO-25-01796","volume":"44","author":"HD Zhu","year":"2026","unstructured":"Zhu HD, Fan WJ, Zhao C, Wang S, Li YL, Jin ZC, et al. Transarterial Chemoembolization Combined With Camrelizumab and Rivoceranib for Unresectable Hepatocellular Carcinoma (CHANCE2005\/CARES-005): A Randomized Phase II Trial. J Clin Oncol. 2026;44:959\u201369.","journal-title":"J Clin Oncol."},{"issue":"8","key":"1834_CR49","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1016\/j.cgh.2023.01.039","volume":"21","author":"AG Singal","year":"2023","unstructured":"Singal AG, Kudo M, Bruix J. Breakthroughs in Hepatocellular Carcinoma Therapies. Clin Gastroenterol Hepatol. 2023;21(8):2135\u201349. https:\/\/doi.org\/10.1016\/j.cgh.2023.01.039.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"4","key":"1834_CR50","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1053\/j.gastro.2025.03.047","volume":"169","author":"AG Singal","year":"2025","unstructured":"Singal AG, Salem R, Pinato DJ, Pillai A. Advances in Locoregional and Systemic Treatments for Hepatocellular Carcinoma. Gastroenterology. 2025;169(4):585\u201399. https:\/\/doi.org\/10.1053\/j.gastro.2025.03.047.","journal-title":"Gastroenterology."},{"issue":"8","key":"1834_CR51","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.jvir.2013.01.494","volume":"24","author":"JL Weintraub","year":"2013","unstructured":"Weintraub JL, Salem R. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science. J Vasc Interv Radiol. 2013;24(8):1123\u201334. https:\/\/doi.org\/10.1016\/j.jvir.2013.01.494.","journal-title":"J Vasc Interv Radiol"},{"key":"1834_CR52","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1159\/000522547","volume":"11","author":"M Kudo","year":"2022","unstructured":"Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, et al. Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma. Liver Cancer. 2022;11:354\u201367.","journal-title":"Liver Cancer."},{"key":"1834_CR53","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.2147\/DDDT.S248850","volume":"14","author":"KC Liu","year":"2020","unstructured":"Liu KC, Hao YH, Lv WF, Jia WD, Ji CS, Zhou CZ, et al. Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma. Drug Des Devel Ther. 2020;14:3461\u20138.","journal-title":"Drug Des Devel Ther."},{"key":"1834_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.783480","volume":"11","author":"F Cao","year":"2021","unstructured":"Cao F, Yang Y, Si T, Luo J, Zeng H, Zhang Z, et al. The efficacy of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a multicenter retrospective study. Front Oncol. 2021;11:783480. https:\/\/doi.org\/10.3389\/fonc.2021.783480.","journal-title":"Front Oncol"},{"key":"1834_CR55","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1159\/000545545","volume":"14","author":"Z Pan","year":"2025","unstructured":"Pan Z, Liu D, Cao J, Fu L, Zhang X, Zhu X, et al. Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 Study. Liver Cancer. 2025;14:601\u201319.","journal-title":"Liver Cancer."},{"key":"1834_CR56","doi-asserted-by":"publisher","first-page":"36426","DOI":"10.1038\/s41598-025-20518-4","volume":"15","author":"H Lu","year":"2025","unstructured":"Lu H, Liang B, Xia X, Kan X, Zheng C. The efficacy and safety analysis of D-TACE combined with donafenib and tislelizumab in recurrent hepatocellular carcinoma after surgery. Sci Rep. 2025;15:36426.","journal-title":"Sci Rep."},{"key":"1834_CR57","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s12072-018-9919-1","volume":"13","author":"T Couri","year":"2019","unstructured":"Couri T, Pillai A. Goals and targets for personalized therapy for HCC. Hepatol Int. 2019;13:125\u201337.","journal-title":"Hepatol Int."},{"issue":"1","key":"1834_CR58","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jhep.2023.02.032","volume":"79","author":"J Tan","year":"2023","unstructured":"Tan J, Fan W, Liu T, Zhu B, Liu Y, Wang S, et al. TREM2(+) macrophages suppress CD8(+) T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma. J Hepatol. 2023;79(1):126\u201340. https:\/\/doi.org\/10.1016\/j.jhep.2023.02.032.","journal-title":"J Hepatol"},{"issue":"24","key":"1834_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202503971","volume":"37","author":"H Wu","year":"2025","unstructured":"Wu H, Lv S, Zhang R, Gu L, Xu J, Li C, et al. Next-Generation Flexible Embolic Systems: Targeted Transarterial Chemoembolization Strategies for Hepatocellular Carcinoma. Adv Mater. 2025;37(24): e2503971. https:\/\/doi.org\/10.1002\/adma.202503971.","journal-title":"Adv Mater."},{"issue":"10474","key":"1834_CR60","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","volume":"405","author":"B Sangro","year":"2025","unstructured":"Sangro B, Kudo M, Erinjeri JP, Qin S, Ren Z, Chan SL, et al. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study. Lancet. 2025;405(10474):216\u201332. https:\/\/doi.org\/10.1016\/S0140-6736(24)02551-0.","journal-title":"Lancet"},{"issue":"10474","key":"1834_CR61","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","volume":"405","author":"M Kudo","year":"2025","unstructured":"Kudo M, Ren Z, Guo Y, Han G, Lin H, Zheng J, et al. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. Lancet. 2025;405(10474):203\u201315. https:\/\/doi.org\/10.1016\/S0140-6736(24)02575-3.","journal-title":"Lancet"},{"key":"1834_CR62","doi-asserted-by":"crossref","unstructured":"Dong J HG, Ogasawara S, et al. LBA2 TALENTACE: a phase \u2162, open-label, randomized study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab\u2009+\u2009bevacizumab (Atezo\u2009+\u2009Bev) or on-demand TACE alone in patients with systemically untreated, intermediate-to-high burden unresectable hepatocellular carcinoma (uHCC). Ann Oncol. 2025.","DOI":"10.1016\/j.annonc.2025.05.542"},{"key":"1834_CR63","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1001\/jamaoncol.2017.5847","volume":"4","author":"SM Yoon","year":"2018","unstructured":"Yoon SM, Ryoo BY, Lee SJ, Kim JH, Shin JH, An JH, et al. Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial. JAMA Oncol. 2018;4:661\u20139.","journal-title":"JAMA Oncol."},{"key":"1834_CR64","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/j.ijrobp.2011.03.019","volume":"82","author":"SM Yoon","year":"2012","unstructured":"Yoon SM, Lim YS, Won HJ, Kim JH, Kim KM, Lee HC, et al. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. Int J Radiat Oncol Biol Phys. 2012;82:2004\u201311.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"1834_CR65","doi-asserted-by":"crossref","unstructured":"Chu HH, Kim JH, Shim JH, Yoon SM, Kim PH, Alrashidi I. Chemoembolization Plus Radiotherapy Versus Chemoembolization Plus Sorafenib for the Treatment of Hepatocellular Carcinoma Invading the Portal Vein: A Propensity Score Matching Analysis. Cancers (Basel). 2020:12.","DOI":"10.3390\/cancers12051116"},{"key":"1834_CR66","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s00432-013-1568-0","volume":"140","author":"M Yang","year":"2014","unstructured":"Yang M, Fang Z, Yan Z, Luo J, Liu L, Zhang W, et al. Transarterial chemoembolisation (TACE) combined with endovascular implantation of an iodine-125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone: a two-arm, randomised clinical trial. J Cancer Res Clin Oncol. 2014;140:211\u20139.","journal-title":"J Cancer Res Clin Oncol."},{"key":"1834_CR67","doi-asserted-by":"publisher","first-page":"29258","DOI":"10.18632\/oncotarget.16491","volume":"8","author":"HT Hu","year":"2017","unstructured":"Hu HT, Luo JP, Li HL, Guo CY, Yao QJ, Geng X, et al. Transarterial chemoembolization combined with computed tomography-guided 125iodine implantation enhances survival in hepatocellular carcinoma patients with portal vein tumor thrombus. Oncotarget. 2017;8:29258\u201368.","journal-title":"Oncotarget."},{"key":"1834_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102622","volume":"72","author":"ZC Jin","year":"2024","unstructured":"Jin ZC, Chen JJ, Zhu XL, Duan XH, Xin YJ, Zhong BY, et al. Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody\/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study. EClinicalMedicine. 2024;72: 102622.","journal-title":"EClinicalMedicine."},{"key":"1834_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2024.108634","volume":"257","author":"L Wang","year":"2024","unstructured":"Wang L, Lin L, Zhou W. Efficacy and safety of transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor in the treatment of advanced hepatocellular carcinoma: A meta-analysis. Pharmacol Ther. 2024;257: 108634. https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108634.","journal-title":"Pharmacol Ther."},{"key":"1834_CR70","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13045-022-01242-2","volume":"15","author":"M Wu","year":"2022","unstructured":"Wu M, Huang Q, Xie Y, Wu X, Ma H, Zhang Y, et al. Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade via combination therapy and PD-L1 regulation. J Hematol Oncol. 2022;15:24.","journal-title":"J Hematol Oncol."},{"key":"1834_CR71","doi-asserted-by":"publisher","first-page":"5527","DOI":"10.1097\/JS9.0000000000001691","volume":"110","author":"TY Zhou","year":"2024","unstructured":"Zhou TY, Tao GF, Zhou GH, Zhang YL, Zhu TY, Chen SQ, et al. Comparison of drug-eluting bead with conventional transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a randomized clinical trial. Int J Surg. 2024;110:5527\u201337.","journal-title":"Int J Surg."},{"issue":"12","key":"1834_CR72","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202412800","volume":"21","author":"W Wang","year":"2025","unstructured":"Wang W, Wu H, Zhang X, Hong Y, Tao S, Cao X, et al. Whole-Component Antigen Nanovaccines Combined With aTIGIT for Enhanced Innate and Adaptive Anti-tumor Immunity. Small. 2025;21(12): e2412800. https:\/\/doi.org\/10.1002\/smll.202412800.","journal-title":"Small."},{"key":"1834_CR73","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1097\/JS9.0000000000000683","volume":"109","author":"QF Chen","year":"2023","unstructured":"Chen QF, Lyu N, Wang X, Jiang XY, Hu Y, Chen S, et al. Cost-effectiveness and prognostic model of hepatic arterial infusion chemotherapy for hepatocellular carcinoma with high tumor burden and\/or Vp4 tumor thrombus compared with sorafenib: a post-hoc analysis of the FOHAIC-1 trial. Int J Surg. 2023;109:3929\u201339.","journal-title":"Int J Surg."},{"issue":"2","key":"1834_CR74","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1148\/radiol.211545","volume":"303","author":"K Zheng","year":"2022","unstructured":"Zheng K, Zhu X, Fu S, Cao G, Li WQ, Xu L, et al. Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial. Radiology. 2022;303(2):455\u201364. https:\/\/doi.org\/10.1148\/radiol.211545.","journal-title":"Radiology."},{"key":"1834_CR75","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41392-023-01663-6","volume":"8","author":"TQ Zhang","year":"2023","unstructured":"Zhang TQ, Geng ZJ, Zuo MX, Li JB, Huang JH, Huang ZL, et al. Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study. Signal Transduct Target Ther. 2023;8:413.","journal-title":"Signal Transduct Target Ther."},{"key":"1834_CR76","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1097\/JS9.0000000000001940","volume":"111","author":"M Zuo","year":"2025","unstructured":"Zuo M, Zheng G, Cao Y, Lu H, Li D, An C, et al. Hepatic arterial chemotherapy infusion combined with tyrosine kinase inhibitors and PD-1 inhibitors for advanced hepatocellular carcinoma with high risk: a propensity score matching study. Int J Surg. 2025;111:104\u201312.","journal-title":"Int J Surg."},{"issue":"5","key":"1834_CR77","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1200\/JCO.21.01963","volume":"40","author":"N Lyu","year":"2022","unstructured":"Lyu N, Wang X, Li JB, Lai JF, Chen QF, Li SL, et al. Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1). J Clin Oncol. 2022;40(5):468\u201380. https:\/\/doi.org\/10.1200\/JCO.21.01963.","journal-title":"J Clin Oncol."},{"key":"1834_CR78","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1097\/JS9.0000000000001889","volume":"111","author":"T Si","year":"2025","unstructured":"Si T, Shao Q, Jassem W, Ma Y, Heaton N. Optimal candidates and surrogate endpoints for HAIC versus Sorafenib in hepatocellular carcinoma: an updated systematic review and meta-analysis. Int J Surg. 2025;111:1203\u201313.","journal-title":"Int J Surg."},{"issue":"2","key":"1834_CR79","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1200\/JCO.21.00608","volume":"40","author":"QJ Li","year":"2022","unstructured":"Li QJ, He MK, Chen HW, Fang WQ, Zhou YM, Xu L, et al. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. J Clin Oncol. 2022;40(2):150\u201360. https:\/\/doi.org\/10.1200\/JCO.21.00608.","journal-title":"J Clin Oncol."},{"key":"1834_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103217","volume":"83","author":"W Gao","year":"2025","unstructured":"Gao W, Pan ZL, Zhao XH, Yang L, Cao JB, Li DY, et al. Donafenib and sintilimab combined with hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma: a prospective, single-arm phase II trial (DoHAICs study). EClinicalMedicine. 2025;83: 103217.","journal-title":"EClinicalMedicine."},{"key":"1834_CR81","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1097\/JS9.0000000000001378","volume":"110","author":"R Guan","year":"2024","unstructured":"Guan R, Zhang N, Deng M, Lin Y, Huang G, Fu Y, et al. Patients with hepatocellular carcinoma extrahepatic metastases can benefit from hepatic arterial infusion chemotherapy combined with lenvatinib plus programmed death-1 inhibitors. Int J Surg. 2024;110:4062\u201373.","journal-title":"Int J Surg."},{"key":"1834_CR82","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1097\/JS9.0000000000001903","volume":"111","author":"L Ma","year":"2025","unstructured":"Ma L, Zhang C, Wen Y, Xing K, Li S, Geng Z, et al. Imaging-based surrogate classification for risk stratification of hepatocellular carcinoma with microvascular invasion to adjuvant hepatic arterial infusion chemotherapy: a multicenter retrospective study. Int J Surg. 2025;111:872\u201383.","journal-title":"Int J Surg."},{"issue":"2","key":"1834_CR83","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1053\/j.gastro.2024.10.038","volume":"168","author":"JPE Davis","year":"2025","unstructured":"Davis JPE, Lim JK, Francis FF, Ahn J. AGA clinical practice update on management of portal vein thrombosis in patients with cirrhosis: expert review. Gastroenterology. 2025;168(2):396-404 e1. https:\/\/doi.org\/10.1053\/j.gastro.2024.10.038.","journal-title":"Gastroenterology"},{"issue":"3","key":"1834_CR84","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1148\/radiol.211806","volume":"303","author":"E Dhondt","year":"2022","unstructured":"Dhondt E, Lambert B, Hermie L, Huyck L, Vanlangenhove P, Geerts A, et al. 90 Y radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase II randomized controlled trial. Radiology. 2022;303(3):699\u2013710. https:\/\/doi.org\/10.1148\/radiol.211806.","journal-title":"Radiology"},{"key":"1834_CR85","doi-asserted-by":"crossref","unstructured":"Fortuny M, De Rosa A, Roca I, Ouchi D, Suarez E, Cadiz A, et al. Hepatocellular carcinoma with macrovascular invasion: Review and survival meta-analysis of initial local therapy using minimal prognostic criteria. Hepatology. 2025.","DOI":"10.1097\/HEP.0000000000001630"},{"key":"1834_CR86","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3350\/cmh.2023.0076","volume":"29","author":"MH Hur","year":"2023","unstructured":"Hur MH, Cho Y, Kim DY, Lee JS, Kim GM, Kim HC, et al. Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis. Clin Mol Hepatol. 2023;29:763\u201378.","journal-title":"Clin Mol Hepatol."},{"issue":"6","key":"1834_CR87","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.jhep.2025.01.005","volume":"82","author":"R Salem","year":"2025","unstructured":"Salem R, Padia SA, Toskich BB, Callahan JD, Fowers KD, Geller BS, et al. Radiation segmentectomy for early hepatocellular carcinoma is curative. J Hepatol. 2025;82(6):1125\u201332. https:\/\/doi.org\/10.1016\/j.jhep.2025.01.005.","journal-title":"J Hepatol"},{"key":"1834_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2024.101367","volume":"29","author":"Y Dong","year":"2024","unstructured":"Dong Y, Yin L, Huang J, Hu D, Sun J, Zhang Z, et al. (99m)Tc\/(90)Y radiolabeled biodegradable gel microspheres for lung shutting fraction assessment and radioembolization in hepatocellular carcinoma theranostics. Mater Today Bio. 2024;29: 101367.","journal-title":"Mater Today Bio."},{"key":"1834_CR89","doi-asserted-by":"publisher","unstructured":"Morris VK, Kennedy EB, Baxter NN, Benson AB 3rd, Cercek A, Cho M, et al. Treatment of metastatic colorectal cancer: ASCO guideline. J Clin Oncol. 2023;41(3):678\u2013700. https:\/\/doi.org\/10.1200\/JCO.22.01690.","DOI":"10.1200\/JCO.22.01690"},{"key":"1834_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.106094","volume":"102","author":"DM Liu","year":"2022","unstructured":"Liu DM, Leung TW, Chow PK, Ng DC, Lee RC, Kim YH, et al. Clinical consensus statement: selective internal radiation therapy with yttrium 90 resin microspheres for hepatocellular carcinoma in Asia. Int J Surg. 2022;102:106094. https:\/\/doi.org\/10.1016\/j.ijsu.2021.106094.","journal-title":"Int J Surg"},{"key":"1834_CR91","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1097\/JS9.0000000000000654","volume":"109","author":"M Deng","year":"2023","unstructured":"Deng M, Cai H, He B, Guan R, Lee C, Guo R. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization, potential conversion therapies for single huge hepatocellular carcinoma: a retrospective comparison study. Int J Surg. 2023;109:3303\u201311.","journal-title":"Int J Surg."},{"issue":"12","key":"1834_CR92","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","volume":"18","author":"V Vilgrain","year":"2017","unstructured":"Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624\u201336. https:\/\/doi.org\/10.1016\/S1470-2045(17)30683-6.","journal-title":"Lancet Oncol."},{"issue":"19","key":"1834_CR93","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","volume":"36","author":"PKH Chow","year":"2018","unstructured":"Chow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, Ong J, et al. SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J Clin Oncol. 2018;36(19):1913\u201321. https:\/\/doi.org\/10.1200\/JCO.2017.76.0892.","journal-title":"J Clin Oncol."},{"issue":"6","key":"1834_CR94","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jhep.2019.08.006","volume":"71","author":"J Ricke","year":"2019","unstructured":"Ricke J, Klumpen HJ, Amthauer H, Bargellini I, Bartenstein P, de Toni EN, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol. 2019;71(6):1164\u201374. https:\/\/doi.org\/10.1016\/j.jhep.2019.08.006.","journal-title":"J Hepatol."},{"issue":"1","key":"1834_CR95","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","volume":"6","author":"E Garin","year":"2021","unstructured":"Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(1):17\u201329. https:\/\/doi.org\/10.1016\/S2468-1253(20)30290-9.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"1834_CR96","doi-asserted-by":"publisher","first-page":"264","DOI":"10.2967\/jnumed.123.266211","volume":"65","author":"E Garin","year":"2024","unstructured":"Garin E, Tselikas L, Guiu B, Chalaye J, Rolland Y, de Baere T, et al. Long-Term Overall Survival After Selective Internal Radiation Therapy for Locally Advanced Hepatocellular Carcinomas: Updated Analysis of DOSISPHERE-01 Trial. J Nucl Med. 2024;65:264\u20139.","journal-title":"J Nucl Med."},{"issue":"12","key":"1834_CR97","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S2468-1253(21)00305-8","volume":"6","author":"D Tai","year":"2021","unstructured":"Tai D, Loke K, Gogna A, Kaya NA, Tan SH, Hennedige T, et al. Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209\u2013678): a single arm, single centre, phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(12):1025\u201335. https:\/\/doi.org\/10.1016\/S2468-1253(21)00305-8.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1834_CR98","doi-asserted-by":"crossref","unstructured":"Correction: Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study. J Immunother Cancer. 2023;11.","DOI":"10.1136\/jitc-2022-005457corr1"},{"key":"1834_CR99","doi-asserted-by":"crossref","unstructured":"de la Torre-Alaez M, Matilla A, Varela M, Inarrairaegui M, Reig M, Lledo JL, et al. Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study. J Immunother Cancer. 2022;10.","DOI":"10.1136\/jitc-2022-005457"},{"key":"1834_CR100","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1158\/1078-0432.CCR-23-0581","volume":"29","author":"YB Lee","year":"2023","unstructured":"Lee YB, Nam JY, Cho EJ, Lee JH, Yu SJ, Kim HC, et al. A Phase I\/IIa Trial of Yttrium-90 Radioembolization in Combination with Durvalumab for Locally Advanced Unresectable Hepatocellular Carcinoma. Clin Cancer Res. 2023;29:3650\u20138.","journal-title":"Clin Cancer Res."},{"key":"1834_CR101","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/oncolo\/oyad331","volume":"29","author":"S Yu","year":"2024","unstructured":"Yu S, Yu M, Keane B, Mauro DM, Helft PR, Harris WP, et al. A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma. Oncologist. 2024;29:270-e413.","journal-title":"Oncologist."},{"key":"1834_CR102","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s00270-019-02346-y","volume":"43","author":"L Zhang","year":"2020","unstructured":"Zhang L, Hu B, Li W, Huang P, Zhang S, Zhong BY, et al. (125) I Irradiation Stent for Hepatocellular Carcinoma with Main Portal Vein Tumor Thrombosis: A Systematic Review. Cardiovasc Intervent Radiol. 2020;43:196\u2013203.","journal-title":"Cardiovasc Intervent Radiol."},{"key":"1834_CR103","doi-asserted-by":"crossref","unstructured":"2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol 2022;28:583\u2013705.","DOI":"10.3350\/cmh.2022.0294"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01834-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01834-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01834-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:02:32Z","timestamp":1790992952000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-026-01834-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":103,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1834"],"URL":"https:\/\/doi.org\/10.1007\/s11912-026-01834-y","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"assertion":[{"value":"7 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This review is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.","order":1,"name":"Ethics","label":"Compliance with ethics guidelines","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"100"}}